Are you Dr. Fox?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 41 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
400 E Jamie Ct
# Myokardi
South San Francisco, CA 94080Phone+1 650-741-0902
Summary
- Dr. Jonathan Fox, MD is a cardiologist in South San Francisco, California. He is currently licensed to practice medicine in Pennsylvania.
Education & Training
- Duke University HospitalFellowship, Cardiovascular Disease, 1990 - 1993
- Duke University HospitalResidency, Internal Medicine, 1987 - 1990
- University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1987
Certifications & Licensure
- PA State Medical License 1993 - 2016
Clinical Trials
- A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome Start of enrollment: 2006 Oct 01
Publications & Presentations
PubMed
- 361 citationsGenotype and lifetime burden of disease in hypertrophic cardiomyopathy insights from the sarcomeric human cardiomyopathy registry (SHaRe)Carolyn Y. Ho, Sharlene M. Day, Euan A. Ashley, Michelle Michels, Alexandre C. Pereira
Circulation. 2018-10-02 - 55 citationsStabilization of Cardiac Function With Diflunisal in Transthyretin (ATTR) Cardiac AmyloidosisGraham Lohrmann, Alexandra Pipilas, Roberta Mussinelli, Deepa M. Gopal, John L. Berk
Journal of Cardiac Failure. 2020-09-01 - 16 citationsUse of Actigraphy (Wearable Digital Sensors to Monitor Activity) in Heart Failure Randomized Clinical Trials: A Scoping ReviewKhalil Anchouche, Malik Elharram, Emily Oulousian, Amir Razaghizad, Robert Avram
The Canadian Journal of Cardiology. 2021-07-10
Press Mentions
- Eidos Therapeutics Announces Positive Phase 2 Data for AG10 in Symptomatic Patients with Mutant or Wild-Type TTR Amyloid CardiomyopathyNovember 11th, 2018
- Eidos Therapeutics Initiates Phase 2 Clinical Trial for AG10 Targeting Transthyretin Amyloidosis CardiomyopathyMay 3rd, 2018
Professional Memberships
- Member